1. All Products
  2. AZTREONAM, 1g, powder, vial
Liste de prix publique

AZTREONAM, 1g, powder, vial

https://unicat.msf.org/cat/product/94000
NST DINJAZTR1V-

Valid Article

The product is supplied (and stored) sterile, it must remain sterile until its use. Sterile = state of being free from all living microorganisms.
6.2.3 - Reserve group antibiotics
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J01DF01
Anatomical Therapeutic Chemical Classification according to WHOCC
PMFE
The order of this product needs to be justified and is only acceptable under certain conditions.
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
https://www.unicat.msf.org/web/image/product.template/588820/image_1920?unique=4b07ae5

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

AZTREONAM

Therapeutic Action

Anti-infective for systemic use

Monobactam antibiotic

Active against aerobic Gram-negative bacteria (incl. Pseudomonas aeruginosa).

Indications

Treatment of severe infections caused by extensively resistant/Carbapenem-Resistant Enterobacterales (CRE) confirmed or suspected metallo-beta-lactamase producer (in combination with ceftazidime/avibactam), and non-severe infections when treatment options are limited.

Treatment of infections caused by Stenotrophomonas maltophilia (second-line for non-CNS infections, third-line for CNS infections).

Third-line treatment of infections caused by Stenotrophomonas maltophilia, in combination with ceftazidime/avibactam.

Alternative treatment in patients with allergy/hypersensibility to other beta-lactam antibiotics (penicillins, cephalosporins, carbapenems) in infections caused by Gram negative bacilli.

Some restricted information has been hidden. Sign in to see this information

Instructions for use

Must be given as IM, IV injection or IV infusion:

  • IM route:
    • Reconstitute the powder vial with 3 ml of water for injection.
    • Shake the vial until complete dissolution of the contents.
  • Direct IV route
    • Reconstitute the powder vial with 10 ml of water for injection.
    • Administer as a slow IV injection (over 3 to 5 minutes).
  • IV Infusion
    • Reconstitute the powder vial with 3 ml of water for injection.
    • Dilute the reconstituted solution in 0.9% NaCl or 5% or 10% dextrose to obtain a solution at 50 ml to 100 ml/g aztreonam.

Dosage and route of administration should be determined by susceptibility of the causative organisms, severity and site of infection, and the condition of the patient.

The antibiotic treatment will be started only once culture and antibiotic susceptibility testing (AST) results are available (in case of an outbreak in hospital settings, discuss with specialist).

Only to be used in health settings where validated microbiology laboratory is available to confirm antimicrobial susceptibility (particularly for Enterobacterales) and detection of carbapenemases.

Precautions for Use

Use with caution in patients with impaired renal or hepatic function.

Storage

  • Below 25ºC
  • After reconstitution/dilution, use the solution immediately.
  • Discard any unused solution.